<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Syncona Limited — News on 6ix</title>
    <link>https://6ix.com/company/syncona-limited</link>
    <description>Latest news and press releases for Syncona Limited on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Thu, 19 Mar 2026 07:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/syncona-limited" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835ed6578dffbe2df12b8fd.webp</url>
      <title>Syncona Limited</title>
      <link>https://6ix.com/company/syncona-limited</link>
    </image>
    <item>
      <title>Syncona Investment Management Limited highlig...</title>
      <link>https://6ix.com/company/syncona-limited/news/syncona-investment-management-limited-highlig</link>
      <guid isPermaLink="true">https://6ix.com/company/syncona-limited/news/syncona-investment-management-limited-highlig</guid>
      <pubDate>Thu, 19 Mar 2026 07:00:00 GMT</pubDate>
      <description>Syncona Investment Management Limited is highlighting its strategy to translate frontier science into therapeutic reality, with a maturing portfolio poised for near-term value creation and shareholder returns, including plans to return £250 million from private company exits. Key clinical milestones are anticipated in the second half of 2026, such as pivotal Phase 3 data from Beacon Therapeutics and Phase 2b data from iOnctura. To strengthen access to early-stage science, Syncona plans preferent</description>
    </item>
    <item>
      <title>Results of General Meeting and Board Changes</title>
      <link>https://6ix.com/company/syncona-limited/news/results-of-general-meeting-and-board-changes</link>
      <guid isPermaLink="true">https://6ix.com/company/syncona-limited/news/results-of-general-meeting-and-board-changes</guid>
      <pubDate>Tue, 03 Mar 2026 11:00:00 GMT</pubDate>
      <description>Syncona Limited announced that all resolutions were duly passed at its general meeting, including the adoption of a new investment policy with 415,412,384 votes for (89.63%) and approval of new long-term incentive arrangements with 406,333,669 votes for (89.39%). Following these approvals, the company intends to appoint a new non-executive director with investment expertise. Rob Hutchinson has stepped down from the board, and remaining directors will serve on board committees, with the exception</description>
    </item>
    <item>
      <title>Quell Clinical Updates</title>
      <link>https://6ix.com/company/syncona-limited/news/quell-clinical-updates</link>
      <guid isPermaLink="true">https://6ix.com/company/syncona-limited/news/quell-clinical-updates</guid>
      <pubDate>Tue, 03 Mar 2026 09:30:00 GMT</pubDate>
      <description>Syncona Limited notes that its portfolio company Quell Therapeutics has initiated a Phase I/II clinical trial for its lead candidate QEL-005 in rheumatoid arthritis and systemic sclerosis, with data expected in CY2027. Additionally, new interim data from the QEL-001 Phase I/II trial in liver transplantation validates Quell&apos;s technology platform, demonstrating safety, persistence, and functional stability of its CAR-Treg cells for over one year, leading Quell to explore partnership opportunities </description>
    </item>
    <item>
      <title>Publication of Circular</title>
      <link>https://6ix.com/company/syncona-limited/news/publication-of-circular-15</link>
      <guid isPermaLink="true">https://6ix.com/company/syncona-limited/news/publication-of-circular-15</guid>
      <pubDate>Thu, 12 Feb 2026 12:00:00 GMT</pubDate>
      <description>Syncona Limited has published a circular detailing proposals to maximize shareholder value, including a new investment and capital allocation policy, and new long-term incentive arrangements for its investment manager, Syncona Investment Management Limited. Key refinements to the capital allocation policy include a commitment to consult on a new policy at the earliest of returning £250 million to shareholders or two years from the approval of the new investment policy, and a limit of £15 million</description>
    </item>
    <item>
      <title>Third Quarter Update</title>
      <link>https://6ix.com/company/syncona-limited/news/third-quarter-update-1</link>
      <guid isPermaLink="true">https://6ix.com/company/syncona-limited/news/third-quarter-update-1</guid>
      <pubDate>Thu, 05 Feb 2026 07:00:00 GMT</pubDate>
      <description>Syncona Limited reported a positive net asset value (NAV) performance for the third quarter ending December 31, 2025, with NAV per share increasing by 3.6% to 173.9p, reaching a total of £1,058.2 million. The Life Science Portfolio saw a 5.0% return, valued at £840.1 million, largely driven by a 20% valuation uplift in Beacon Therapeutics following its $75 million Series C financing. Over the nine months to December 31, 2025, NAV per share returned 1.8%. The company deployed £52.6 million in the</description>
    </item>
    <item>
      <title>Beacon raises $75m in oversubscribed Series C</title>
      <link>https://6ix.com/company/syncona-limited/news/beacon-raises-dollar75m-in-oversubscribed-series-c</link>
      <guid isPermaLink="true">https://6ix.com/company/syncona-limited/news/beacon-raises-dollar75m-in-oversubscribed-series-c</guid>
      <pubDate>Thu, 08 Jan 2026 12:01:00 GMT</pubDate>
      <description>Syncona Limited has committed $24.5 million to Beacon Therapeutics&apos; oversubscribed $75 million Series C financing, which will accelerate commercial preparations for its gene therapy, laru-zova, and advance pipeline candidates. This investment has resulted in a £29.3 million write-up of Syncona&apos;s holding in Beacon, a 20.0 per cent uplift to its value as of September 30, 2025. Following this financing, Syncona&apos;s holding value in Beacon will be $237.6 million, and its ownership stake will be 38.4 p</description>
    </item>
    <item>
      <title>Total Voting Rights</title>
      <link>https://6ix.com/company/syncona-limited/news/total-voting-rights-404</link>
      <guid isPermaLink="true">https://6ix.com/company/syncona-limited/news/total-voting-rights-404</guid>
      <pubDate>Fri, 28 Nov 2025 18:00:00 GMT</pubDate>
      <description>Syncona Limited has announced that as of 28 November 2025, its total issued ordinary shares stand at 672,549,420, with 64,356,396 shares held in treasury, resulting in a total of 608,193,024 voting rights. This figure serves as the denominator for shareholders to determine notification requirements under the FCA&apos;s Disclosure Guidance and Transparency Rules.
                Disclaimer*</description>
    </item>
    <item>
      <title>Issue of shares pursuant to incentive scheme</title>
      <link>https://6ix.com/company/syncona-limited/news/issue-of-shares-pursuant-to-incentive-scheme</link>
      <guid isPermaLink="true">https://6ix.com/company/syncona-limited/news/issue-of-shares-pursuant-to-incentive-scheme</guid>
      <pubDate>Mon, 17 Nov 2025 07:00:00 GMT</pubDate>
      <description>Syncona Limited will issue 334,788 new ordinary shares, representing approximately 0.055% of its existing issued shares, to satisfy realisations under its long-term incentive scheme. These shares were valued at £0.996 each, based on the closing mid-market price on November 13, 2025. The new shares will rank pari passu with existing shares and are subject to a one-year restriction on sale or transfer by the recipient. Admission to the Official List and trading on the London Stock Exchange is expe</description>
    </item>
    <item>
      <title>Half-year Report</title>
      <link>https://6ix.com/company/syncona-limited/news/half-year-report-327</link>
      <guid isPermaLink="true">https://6ix.com/company/syncona-limited/news/half-year-report-327</guid>
      <pubDate>Thu, 13 Nov 2025 07:00:00 GMT</pubDate>
      <description>Syncona Limited reported interim results for the six months ended 30 September 2025, with net assets of £1,020.9 million, a decrease of 1.7% from the previous period, primarily due to a £15.9 million write-down in the CRT Pioneer Fund. The life science portfolio was valued at £750.2 million, also down 1.7%, though the remainder of the portfolio showed positive performance. The company has a capital pool of £270.7 million and is funded to deliver eight key value inflection points, with five antic</description>
    </item>
    <item>
      <title>Autolus reports Q3 2025 Financial Results</title>
      <link>https://6ix.com/company/syncona-limited/news/autolus-reports-q3-2025-financial-results</link>
      <guid isPermaLink="true">https://6ix.com/company/syncona-limited/news/autolus-reports-q3-2025-financial-results</guid>
      <pubDate>Wed, 12 Nov 2025 16:30:00 GMT</pubDate>
      <description>Syncona Limited&apos;s portfolio company, Autolus Therapeutics, reported third quarter 2025 results showing $21.1 million in AUCATZYL net product revenue and $7.6 million in deferred revenue, with 60 authorized treatment centers activated ahead of schedule. Clinical data for severe refractory systemic lupus erythematosus demonstrated no ICANS or high-grade CRS, with 83% achieving remission and 50% achieving complete renal response. The company also bolstered its leadership team to support future grow</description>
    </item>
    <item>
      <title>Strategy update</title>
      <link>https://6ix.com/company/syncona-limited/news/strategy-update-5</link>
      <guid isPermaLink="true">https://6ix.com/company/syncona-limited/news/strategy-update-5</guid>
      <pubDate>Tue, 21 Oct 2025 06:00:00 GMT</pubDate>
      <description>Syncona Limited announced proposals to maximize shareholder value, focusing on returning £250 million of net proceeds to shareholders from potential sales of mature private portfolio companies. The structure of these returns, which may include tender offers, share buybacks, or special dividends, will be determined at the time of realization. A new investment objective and policy will prioritize realizing maximum value from mature portfolio companies and returning cash to shareholders. Syncona wi</description>
    </item>
    <item>
      <title>Holding(s) in Company</title>
      <link>https://6ix.com/company/syncona-limited/news/holdings-in-company-568</link>
      <guid isPermaLink="true">https://6ix.com/company/syncona-limited/news/holdings-in-company-568</guid>
      <pubDate>Thu, 18 Sep 2025 16:30:00 GMT</pubDate>
      <description>On September 18, 2025, Syncona Limited announced that Saba Capital Management, L.P. crossed a threshold on September 16, 2025, regarding major holdings. Saba Capital&apos;s total voting rights in Syncona reached 5.187147%. This comprises 0.882015% of voting rights attached to shares, representing 5,361,398 shares, and 4.305132% of voting rights through financial instruments. The latter is attributed to 26,169,102 voting rights related to a cash-settled Total Return Swap expiring on November 28, 2025.</description>
    </item>
    <item>
      <title>Beacon positive interim data for Phase 2 studies</title>
      <link>https://6ix.com/company/syncona-limited/news/beacon-positive-interim-data-for-phase-2-studies</link>
      <guid isPermaLink="true">https://6ix.com/company/syncona-limited/news/beacon-positive-interim-data-for-phase-2-studies</guid>
      <pubDate>Thu, 04 Sep 2025 12:05:00 GMT</pubDate>
      <description>Syncona Limited reports positive interim data from Beacon Therapeutics&apos; Phase 2 SKYLINE and DAWN trials of laru-zova for X-linked retinitis pigmentosa (XLRP). The data, presented at the EURETINA 2025 Conference, showed that laru-zova was generally well-tolerated by SKYLINE participants through month 36 and DAWN participants at 9 months or beyond. Key findings include sustained improvements in low luminance visual acuity and microperimetry. Beacon has completed enrollment in its pivotal VISTA tri</description>
    </item>
    <item>
      <title>Autolus reports Q2 2025 Financial Results</title>
      <link>https://6ix.com/company/syncona-limited/news/autolus-reports-q2-2025-financial-results</link>
      <guid isPermaLink="true">https://6ix.com/company/syncona-limited/news/autolus-reports-q2-2025-financial-results</guid>
      <pubDate>Wed, 13 Aug 2025 15:30:00 GMT</pubDate>
      <description>Autolus reports Q2 2025 Financial Results.</description>
    </item>
    <item>
      <title>First Quarter Update</title>
      <link>https://6ix.com/company/syncona-limited/news/first-quarter-update</link>
      <guid isPermaLink="true">https://6ix.com/company/syncona-limited/news/first-quarter-update</guid>
      <pubDate>Thu, 07 Aug 2025 06:00:00 GMT</pubDate>
      <description>First Quarter Update.</description>
    </item>
    <item>
      <title>Directorate Change</title>
      <link>https://6ix.com/company/syncona-limited/news/directorate-change-416</link>
      <guid isPermaLink="true">https://6ix.com/company/syncona-limited/news/directorate-change-416</guid>
      <pubDate>Tue, 05 Aug 2025 13:07:00 GMT</pubDate>
      <description>Directorate Change.</description>
    </item>
    <item>
      <title>Result of AGM</title>
      <link>https://6ix.com/company/syncona-limited/news/result-of-agm-515</link>
      <guid isPermaLink="true">https://6ix.com/company/syncona-limited/news/result-of-agm-515</guid>
      <pubDate>Tue, 05 Aug 2025 13:06:00 GMT</pubDate>
      <description>Result of AGM.</description>
    </item>
    <item>
      <title>Notice of AGM</title>
      <link>https://6ix.com/company/syncona-limited/news/notice-of-agm-265</link>
      <guid isPermaLink="true">https://6ix.com/company/syncona-limited/news/notice-of-agm-265</guid>
      <pubDate>Wed, 02 Jul 2025 06:00:00 GMT</pubDate>
      <description>Notice of AGM.</description>
    </item>
    <item>
      <title>Strategy Update</title>
      <link>https://6ix.com/company/syncona-limited/news/strategy-update-6</link>
      <guid isPermaLink="true">https://6ix.com/company/syncona-limited/news/strategy-update-6</guid>
      <pubDate>Thu, 19 Jun 2025 06:00:00 GMT</pubDate>
      <description>Strategy Update.</description>
    </item>
    <item>
      <title>Final Results</title>
      <link>https://6ix.com/company/syncona-limited/news/final-results-303</link>
      <guid isPermaLink="true">https://6ix.com/company/syncona-limited/news/final-results-303</guid>
      <pubDate>Thu, 19 Jun 2025 06:00:00 GMT</pubDate>
      <description>Final Results.</description>
    </item>
  </channel>
</rss>